查詢結果分析
相關文獻
- 治療第二型糖尿病藥物Repaglinide
- 從JNCVI及UKPDS談第二型糖尿病的血壓控制
- 從「英國前瞻性糖尿病研究」談糖尿病的血糖控制
- 第二型糖尿病之口服藥物治療趨勢
- Increased Urinary Endothelin-1 Excretion in Newly Diagnosed Type 2 Diabetic Patients
- 從ABCD及FACET臨床試驗談鈣離子阻斷劑在糖尿病病人的使用
- 第二型糖尿病患者執行有氧運動之血糖立即反應和長期成效--前驅研究
- 糖尿病新知--MODY
- 第二型糖尿病之血脂異常
- Lack of Effect of Simvastatin on Insulin Sensitivity in Type 2 Diabetic Patients with Hypercholesterolaemia: Results from a Double-Blind, Randomized, Placebo-Controlled Crossover Study
頁籤選單縮合
題 名 | Liraglutide用於第二型糖尿病治療=Liraglutide in Treatment of Type II Diabetes |
---|---|
作 者 | 楊璦瑜; 溫燕霞; | 書刊名 | 藥學雜誌 |
卷 期 | 30:4=121 2014.12[民103.12] |
頁 次 | 頁48-54 |
分類號 | 415.937、415.937 |
關鍵詞 | 第二型糖尿病; GLP-1 analog; Liraglutide; Exenatide; Sitagliptin; |
語 文 | 中文(Chinese) |
中文摘要 | 第二型糖尿病是一個漸進性的疾病,其特徵是胰島素阻抗及 β-cell 功能逐漸衰 竭,若未積極治療控制,常見有多種併發症不只影響病人健康,也大幅增加社會醫 療資源的負擔。研究顯示長期使用胰島素促泌素,可能會加速 β-cel 衰竭。治療用藥 應選用 β-cell preservative,例如 GLP-1作用類似物。Liraglutide 是人類 GLP-1類似物 (97%的同源性),用於治療第二型糖尿病,為一天一次的皮下注射劑型。 Liraglutide 最主要作用在胰臟的 β-cell,增加葡萄糖依賴的胰島素分泌,可降低 血糖同時防止低血糖發生;作用於胰臟的 α-cell,降低昇糖激素的分泌。另外也抑制 胃排空、胃酸分泌,降低餐後高血糖;增加飽食感,減少食物的攝取。 本文介紹 liraglutide 在臨床試驗的療效及對心血管疾病的影響。從臨床試驗比較 liraglutide 與 exenatide 及 liraglutide 與 sitagliptin 的療效差異,以提供醫療人員參考。 |
英文摘要 | Type II diabetes is a progressive disease characterized by insulin resistance and β-cell function gradual failure, without aggressive treatment will produce a variety of complications affecting mortality, also increases the burden on society medical resources. Studies have shown that long-term use of insulin secretagogues may run out of β-cell. Drug treatment should be used in β-cell preservative, such as the role of GLP-1 analog. Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue, is a treatment for T2DM. It is administered as a once-daily subcutaneous injection. Liraglutide's major role in pancreatic β-cell, increase glucose-dependent insulin secretion, can reduce blood sugar, and also to prevent hypoglycemia through the effect on the pancreas α-cell, reduces the secretion of glucagon. Further, it also inhibits gastric emptying, gastric acid secretion, reduce postprandial hyperglycemia; increase satiety and reduce food intake. This article describes the efficacy of liraglutide in clinical trials and impact on cardiovascular disease. Comparing liraglutide with exenatide, liraglutide efficacy with sitagliptin efficacy, differences in clinical trials provides medical officers with references. |
本系統中英文摘要資訊取自各篇刊載內容。